IPLEX-COMUNICADO URGENTE

nobregapaulo7 Qui Out 30, 2008 9:39 pm

TEXTO TRADUZIDO:
De: e.esparza (e.esparza@comcast.net)

URGENTE! ENVIE ESTA INFORMAÇÃO IMPORTANTE AOS PACIENTES, À FAMÍLIA E AOS AMIGOS DO ALS AGORA! SEJA LÁ SE VOCÊ PODE! SUA SUSTENTAÇÃO É IMPERATIVA! COM SUA AJUDA NÓS PODEMOS SUCEDER! SOMENTE 2 SEMANAS SAIRAM! PARA A LIBERAÇÃO IMEDIATA DEMONSTRAÇÃO DE LOU GEHRIG'S DISEASE! TERÇA-FEIRA, NOVEMBRO 11, 2008 10AM a 4PM U.S. Gramado dianteiro ocidental do edifício do Capitólio (acessível deficiente), WASHINGTON, C.C. Disputa legal do protesto dos pacientes do ALS que impede o acesso à droga do salvamento GENENTECH-TERCICA*-INSMED: LIBERE IPLEX AGORA! Suporte pacientes com esclerose lateral Amyotrophic (Lou Gehrig's Disease) agora juntando-se nossa demonstração para forçar Genentech, Tercica e Insmed para resolver sua disputa legal e para liberar IPLEX para fornecer o relevo do sintoma para esta doença horrívea. Nós estamos convidando todas as pessoas com ALS, cuidadors, amigos, família, meios e outro para juntar-se nos em protestar este travesti devastador de justiça. IPLEX é uma farmacêutica biomedicável que reduza os sintomas para pacientes do ALS e forneça o relevo e melhorias significativos, uma realização previamente unheard-of embora tornado não especificamente para essa finalidade. Apesar disso, março em 7, 2007, em um acordo de estabelecimento entre Genentech, em Tercica e em Insmed removeu IPLEX dos pacientes do ALS nos E.U. e no mundo inteiro, à excecpção dos pacientes italianos do ALS, uma exclusão cruel do estabelecimento. Quando os pacientes italianos do ALS tirarem proveito de IPLEX, o descanso do mundo do ALS sofre o debilitation, a privação e a morte. IPLEX é uma versão melhorada de Increlex, uma droga pretendida original melhorar a estatura curta severa do crescimento. Quando ambas as drogas realizarem aquela a um maior ou a pouco grau, simplesmente IPLEX melhora significativamente a qualidade de vida para pacientes do ALS. Apesar disso, as pessoas com ALS perdidas alcançam a IPLEX e são oferecidas Increlex. Após muitos meses do uso, é desobstruído que IPLEX é a única droga que oferece o grande benefício possível aos pacientes do ALS. Não obstante, permanece não disponível devido à avidez de Genentech, de Tercica e de Insmed, tudo de quem concordou a este acordo de estabelecimento imoral em nome do lucro incorporado e pessoal. As tentativas de obter IPLEX falharam, apesar do contato contínuo com os CEOs de todos os três corporaçõs, de meios, de magistratura, de advogados, de Senators, de representantes e de outros oficiais do governo. Cada um culpas ou pontos aos outro. Ninguém toma a responsabilidade para este travesti. A demonstração pública é agora o único recurso deixado à comunidade do ALS. O ALS rouba suas vítimas de todos os músculos voluntários, sentenciando suas vítimas a o que é chamado “uma breve vida em um caixão de vidro” e morte dentro de 2 a 4 anos. IPLEX é a única droga contudo tornado que retarda significativamente e inverte em alguns casos esta doença devastador. Nossa esperança é esta demonstração alertará o público, nosso congresso e os meios para ajudar a força Genentech, Tercica e Insmed a liberar IPLEX. Junte-se nos neste esforço crítico. A ajuda faz IPLEX disponível aos pacientes do ALS para melhorar a qualidade de suas vidas, para entretanto por muito tempo que é. Os detalhes científicos e da demonstração da atividade são unidos. Para mais informações, contate por favor: Andrea Reimers, RN Email: andyvaughn@roadrunner.com Telefone: 805-497-9844 Ou Kathy Thompson Email: quiltersdreambatting@juno.com Telefone: 757-407-9860 Ou Stephen Byer Email: bsbyer@mhtc.net Telefone: 608-698-4200 * Tercica Inc. está atualmente no processo de aquisição Ipsen SA, France --------------------------------------------------------------------------------
TEXTO ORIGINAL

URGENT! FORWARD THIS IMPORTANT INFORMATION TO ALS PATIENTS, FAMILY AND FRIENDS NOW! BE THERE IF YOU CAN! YOUR SUPPORT IS IMPERATIVE! WITH YOUR HELP WE CAN SUCCEED! ONLY 2 WEEKS LEFT! FOR IMMEDIATE RELEASE LOU GEHRIG’S DISEASE DEMONSTRATION! TUESDAY, NOVEMBER 11, 2008 10AM to 4PM U.S. Capitol Building West Front Lawn (handicapped accessible), WASHINGTON, D.C. ALS Patients Protest Legal Dispute Preventing Access to Life-Saving Drug GENENTECH-TERCICA*-INSMED: RELEASE IPLEX NOW! Support patients with Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease) now by joining our demonstration to force Genentech, Tercica and Insmed to resolve their legal dispute and release IPLEX to provide symptom relief for this horrible disease. We are calling on all persons with ALS, caregivers, friends, family, media and others to join us in protesting this devastating travesty of justice. IPLEX is a biomedical pharmaceutical that reduces the symptoms for ALS patients and provides significant relief and improvements, a previously unheard-of achievement although not specifically developed for that purpose. Despite that, on March 7, 2007, a settlement agreement between Genentech, Tercica and Insmed removed IPLEX from ALS patients in the US and throughout the world, with the exception of Italian ALS patients, a cruel settlement exclusion. While Italian ALS patients benefit from IPLEX, the rest of the ALS world suffers debilitation, deprivation and death. IPLEX is an improved version of Increlex, a drug originally intended to improve severe short growth stature. While both drugs accomplish that to a greater or lesser degree, only IPLEX significantly improves the quality of life for ALS patients. Despite that, persons with ALS lost access to IPLEX and are offered Increlex. After many months of usage, it is clear that IPLEX is the only drug that offers the greatest possible benefit to ALS patients. Nevertheless, it remains unavailable due to the greed of Genentech, Tercica and Insmed, all of whom agreed to this immoral settlement agreement in the name of corporate and personal profit. Attempts to procure IPLEX have failed, despite continuous contact with the CEO’s of all three corporations, media, judiciary, attorneys, Senators, Representatives and other government officials. Each blames or points to the other. No one takes responsibility for this travesty. Public demonstration is now the only recourse left to the ALS community. ALS robs its victims of all voluntary muscles, sentencing its victims to what is called “a brief life in a glass coffin” and death within 2 to 4 years. IPLEX is the only drug yet developed that significantly slows and in some cases reverses this devastating disease. Our hope is this demonstration will alert the public, our congress and the media to help force Genentech, Tercica and Insmed to release IPLEX. Join us in this critical effort. Help make IPLEX available to ALS patients to improve the quality of their lives, for however long that is. Scientific and demonstration activity details are attached. For further information, please contact: Andrea Reimers, RN Email: andyvaughn@roadrunner.com Tel: 805-497-9844 Or Kathy Thompson Email: quiltersdreambatting@juno.com Tel: 757-407-9860 Or Stephen Byer Email: bsbyer@mhtc.net Tel: 608-698-4200 * Tercica Inc. is currently in process of acquisition by Ipsen SA, France --------------------------------------------------------------------------------
'
URGENT!

FORWARD THIS IMPORTANT INFORMATION TO ALS PATIENTS, FAMILY AND FRIENDS NOW!

BE THERE IF YOU CAN! YOUR SUPPORT IS IMPERATIVE!

WITH YOUR HELP WE CAN SUCCEED! ONLY 2 WEEKS LEFT!

FOR IMMEDIATE RELEASE

LOU GEHRIG’S DISEASE DEMONSTRATION!

TUESDAY, NOVEMBER 11, 2008

10AM to 4PM

U.S. Capitol Building West Front Lawn (handicapped accessible), WASHINGTON, D.C.

ALS Patients Protest Legal Dispute Preventing Access to Life-Saving Drug

GENENTECH-TERCICA*-INSMED: RELEASE IPLEX NOW!

Support patients with Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease) now by joining our demonstration to force Genentech, Tercica and Insmed to resolve their legal dispute and release IPLEX to provide symptom relief for this horrible disease. We are calling on all persons with ALS, caregivers, friends, family, media and others to join us in protesting this devastating travesty of justice.

IPLEX is a biomedical pharmaceutical that reduces the symptoms for ALS patients and provides significant relief and improvements, a previously unheard-of achievement although not specifically developed for that purpose. Despite that, on March 7, 2007, a settlement agreement between Genentech, Tercica and Insmed removed IPLEX from ALS patients in the US and throughout the world, with the exception of Italian ALS patients, a cruel settlement exclusion. While Italian ALS patients benefit from IPLEX, the rest of the ALS world suffers debilitation, deprivation and death.

IPLEX is an improved version of Increlex, a drug originally intended to improve severe short growth stature. While both drugs accomplish that to a greater or lesser degree, only IPLEX significantly improves the quality of life for ALS patients. Despite that, persons with ALS lost access to IPLEX and are offered Increlex. After many months of usage, it is clear that IPLEX is the only drug that offers the greatest possible benefit to ALS patients. Nevertheless, it remains unavailable due to the greed of Genentech, Tercica and Insmed, all of whom agreed to this immoral settlement agreement in the name of corporate and personal profit.

Attempts to procure IPLEX have failed, despite continuous contact with the CEO’s of all three corporations, media, judiciary, attorneys, Senators, Representatives and other government officials. Each blames or points to the other. No one takes responsibility for this travesty.

Public demonstration is now the only recourse left to the ALS community.

ALS robs its victims of all voluntary muscles, sentencing its victims to what is called “a brief life in a glass coffin” and death within 2 to 4 years. IPLEX is the only drug yet developed that significantly slows and in some cases reverses this devastating disease.

Our hope is this demonstration will alert the public, our congress and the media to help force Genentech, Tercica and Insmed to release IPLEX. Join us in this critical effort. Help make IPLEX available to ALS patients to improve the quality of their lives, for however long that is.

Scientific and demonstration activity details are attached. For further information, please contact:

Andrea Reimers, RN

Email: andyvaughn@roadrunner.com

Tel: 805-497-9844

Or

Kathy Thompson

Email: quiltersdreambatting@juno.com

Tel: 757-407-9860

Or

Stephen Byer

Email: bsbyer@mhtc.net

Tel: 608-698-4200

* Tercica Inc. is currently in process of acquisition by Ipsen SA, France

--------------------------------------------------------------------------------